The United States can benefit from taking and adapting certain elements of European countries’ systems and methods of assessing value, says Patricia Danzon, PhD, the Celia Moh Professor at The Wharton School, University of Pennsylvania.
The United States can benefit from taking and adapting certain elements of European countries’ systems and methods of assessing value, says Patricia Danzon, PhD, the Celia Moh Professor at The Wharton School, University of Pennsylvania.
Transcript (slightly modified)
Is there something that Europe does well in assessing value that the United States can adopt or adapt?
There’s not a single European system that I’d say we would want to adopt wholesale, but there are elements. I think the United Kingdom’s system at measuring health outcomes, using QALYs [quality-adjusted life years], and various spinoffs of QALYs has been refined. It’s really in the English-speaking countries, so it includes the UK, Canada, Australia, and that literature on health outcomes measurement really is the most advanced in the world. I think we can definitely learn something from that, and I would say American academics contribute to that literature. It may not be used by our payers, but the academics contribute to that literature.
The system that is applied in the UK through NICE obviously uses a much lower threshold for willingness to pay—they use the £20,000 per QALY which is way below what we in the United States are willing to pay for health. So, if we were to adopt a system, based on cost per QALY, we would obviously use a higher threshold. But there are other elements of other countries’ systems that I think are worth noting, and one in particular—Germany has a system where when a new drug is launched, the drug can be on the market at a price that the company names for a year. During which, the payer assesses the value and decides whether or not to simply pay the existing price, or do a more thorough evaluation of the benefits of the drug and their appropriate price.
That is a way of getting the drugs on the market right away, without waiting for the launch to occur after the evaluation has been done—which is more of the UK approach, you first do the evaluation, and then you get the reimbursement. The German approach says you can launch with a conditional price, while we do some preliminary evaluation. That, I think, is a better way of doing things because it gets new drugs to market but still gives the payer the chance to evaluate the effectiveness and make an assessment of price relative to value.
Race/Ethnicity May Influence Local Recurrence in DCIS, Adjuvant Treatment
December 6th 2023Disparities in 10-year local recurrence following breast-conserving surgery were seen among women with ductal carcinoma in situ (DCIS) treated over a nearly 4-decade span at Memorial Sloan Kettering Cancer Center, with Black women having the highest rate.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
SABCS 2023 Sessions Touch on "Every Aspect of Breast Cancer"
December 4th 2023The 46th annual San Antonio Breast Cancer Symposium will take place December 5-9, with new and experienced attendees able to choose and learn from a schedule overflowing with the latest developments in breast cancer science and research.
Read More
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
Evaluating Label Warnings, Switching Rates in Patients With Psoriasis Initiating New Treatment
November 9th 2023Posters presented at the 2023 Fall Clinical Dermatology Conference evaluated how label warnings may affect new treatment initiation and real-word switching patterns for patients starting risankizumab.
Read More
Innovation in Value-Based Care Requires More Data, Patient-Centered Thinking
November 9th 2023In a panel discussion at the 2023 Patient-Centered Oncology Care® meeting held in Nashville, Tennessee, experts discussed the Enhancing Oncology Model and themes in the movement toward value-based care in oncology.
Read More